Results 91 to 100 of about 7,833 (210)

The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients

Клиническая онкогематология, 2019
Despite advances in chemo-immunotherapy of chronic lymphocytic leukemia, a choice of therapy is a frequent challenge in patients with a refractory form of the disease, autoimmune hemolytic complications, and also in high-risk patients with cytogenetic ...
Nadezhda Viktorovna Kurkina, E. A. Repina, N. N. Mashnina   +2 more
doaj   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Evolving treatments for Sjögren disease: current approaches and emerging targets

Internal Medicine Journal, EarlyView.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani, Adrian Y. S. Lee, Maureen Rischmueller, Alberta Hoi   +3 more
wiley   +1 more source

Development of a Selective Labeling Probe for Bruton’s Tyrosine Kinase Quantification in Live Cells

, 2018
As a key regulator of the B-cell receptor signaling pathway, Bruton’s tyrosine kinase (Btk) has emerged as an important therapeutic target for various malignancies and autoimmune disorders.
Zhengying Pan (1717066), Xiafeng Wang (5099939), Jiahui Chen (1818361), Fengli He (572513)   +3 more
core   +1 more source

Kinase selectivity of TAS5315.

, 2023
Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
Satoru Iguchi (14670687), Yohei Yoshiga (111997), Kenji Tanaka (692662), Daisuke Kajiwara (14670693), Ryusuke Kaneko (14670690), Yoshinori Nakachi (14670696), Atsushi Shimizu (1862), Fumihito Hosoi (2538544), Naruto Noma (14670699), Daichi Akasaka (14670684)   +9 more
core   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Both proline-rich sequences in the TH region of Bruton’s tyrosine kinase stabilize intermolecular interactions with the SH3 domain

, 2001
The Tec homology (TH) region located N-terminal to the Src homology 3 (SH3) domain of Bruton’s tyrosine kinase (Btk) contains two proline-rich SH3-binding sequences (PRRs).
Torleif Härd, Härd, T, Smith, C.I.Edvard, C.I.Edvard Smith, Hansson, Henrik, Härd, Torleif, Smith, CIE, Henrik Hansson, Hansson, H   +8 more
core   +1 more source

Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

Biomarker Insights, 2015
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis.
Nadine Kutsch, Reinhard Marks, Richard Ratei, Thomas K. Held, Martin Schmidt-Hieber   +4 more
doaj   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Bruton’s tyrosine kinase is a substrate of calpain in human platelets

, 2001
Platelet-associated Bruton’s tyrosine kinase (Btk) was completely cleaved if treated with calcium ionophore A23187 with appearance of a proteolytic product of 27 kDa size.
Ramars, Amanchy S. S., Ochs, Hans D., Dash, Debabrata, Amanchy S.S. Ramars, Ramars, Amanchy S.S., Mukhopadhyay, Saikat, Saikat Mukhopadhyay, Hans D. Ochs, Debabrata Dash   +8 more
core   +1 more source